电解质溶液斯特罗芬丁的心脏保护作用以及可能的潜在机制
Min Chen1,2, Yingying Xiao3, Jijian Zheng1
1Department of Anesthesiology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frontiers in pharmacology
|January 20, 2025
概括
斯特罗芬丁 (SF) 通过减少细胞损伤和改善心脏功能来保护心肌梗塞 (MI) 后的心脏. 这种电解质溶液增强了自,这是其心脏保护作用的关键机制.
科学领域:
- 心脏病学 心脏病学
- 密集护理医学 密集护理医学
- 生物化学 生物化学
背景情况:
- 斯特罗芬丁 (SF) 是一种在重症监护中广泛使用的电解质溶液.
- 它解决了心肌梗塞 (MI) 后的酸失衡,离子波动和能量代谢问题.
- 在心脏病发作后的SF心脏保护机制在很大程度上仍然未被阐明.
研究的目的:
- 调查斯特罗芬丁 (SF) 对心肌梗塞 (MI) 后心脏损伤的保护作用.
- 阐明底层的分子机制,特别关注涉及SF心脏保护的自.
主要方法:
- 在接受心脏病手术之前,小鼠先用SF进行预治疗.
- 评估的是活性氧物种 (ROS),道染色,心脏纤维化和心脏表现.
- 用RNA测序 (RNA-seq) 和西式涂抹来分析基因表达和蛋白质水平,包括自标志物.
主要成果:
- SF预处理显著减少了ROS和TUNEL阳性细胞,心脏病发作大小和心脏纤维化.
- SF在MI小鼠中改善了心脏表现,并将基因表达特征转移到虚假对照.
- SF上调自相关基因和增强自流量,这对其保护作用至关重要.
结论:
- 斯特罗芬丁 (SF) 显示出显著的心脏保护作用,防止后心脏病损伤.
- 通过SF介导的自调节是其益处的关键机制.
- 这项研究强调了电解质溶液在心脏病后重症监护中的新角色.
相关概念视频
Heart Failure Drugs: Inotropic Agents
511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Antihypertensive Drugs: Potassium-Sparing Diuretics
443
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
443


